Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 13,360 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Intracranial CNS Disorder Clear all

Conditions: Drug-Resistant Focal Epilepsy
Interventions: Temporal Interference Stimulation, Direct Electrical Stimulation; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Krabbe Disease
Interventions: FBX-101; Biological
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Brain Injuries, Traumatic
Interventions: Blood draw at Days 0, 7, 14, and 21; Other
Lead sponsor: Banyan Biomarkers, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 5
States / cities: Vista, California • Gainesville, Florida • Decatur, Georgia + 2 more

Conditions: Granulin Mutation
Interventions: FRM-0334, Placebo; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 5
States / cities: San Francisco, California • Orlando, Florida • Boston, Massachusetts + 2 more

Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Interventions: Placebo, AVP-786; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 93
States / cities: Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 68 more

Conditions: Glioblastoma, Gliosarcoma
Interventions: Temozolomide, Depatuxizumab mafodotin, Radiation, Placebo for ABT-414; Drug · Radiation
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 691 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 68
States / cities: Phoenix, Arizona • Springdale, Arkansas • Los Angeles, California + 52 more

Conditions: Tourette Syndrome, Obsessive Compulsive Disorder
Interventions: Not listed
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 5 Years to 17 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1989
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: SCN2A-DEE, Epilepsy
Interventions: Not listed
Lead sponsor: Praxis Precision Medicines; Industry
Eligibility: 1 Year to 16 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Concussion, Brain, Mild Traumatic Brain Injury
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 11 Years to 17 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers
Interventions: Not listed
Lead sponsor: Neurogen Biomarking LLC; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Chicago, Illinois • Dearborn, Michigan • Flint, Michigan + 2 more

Conditions: Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Behcet's Disease, Kawasaki Disease, Henoch-schoenlein Purpura, Vasculitis, Central Nervous System, Drug-induced Necrotizing Vasculitis
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Sleep, Alzheimer Disease
Interventions: Behavioral sleep education, Education only; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Los Angeles, California • North Hills, California

Conditions: Brain Tumor, Glioblastoma, Medulloblastoma, Ependymoma, Anaplastic Astrocytoma
Interventions: Dendritic Cells, Imiquimod; Biological · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Not listed
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Stroke Survivors
Interventions: Current stimulator; Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Brain Tumor Recurrent
Interventions: 5-Azacytidine; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 1 Year to 21 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain Tumor, Cancer
Interventions: Zotiraciclib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 15 Years to 99 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 2
States / cities: Jacksonville, Florida • Bethesda, Maryland

Conditions: Stroke
Interventions: Modified cognitive behavioral therapy plus problem-solving, usual care; Behavioral · Other
Lead sponsor: University of Washington; Other
Eligibility: 21 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sphingomyelin Lipidosis
Interventions: Olipudase alfa; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Up to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Parkinson's Disease
Interventions: Fetal porcine cells, Neurocell-PD; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 40 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Brain Injuries, Traumatic
Interventions: Head and Intraocular Trauma Tool, SCAT-5; Device · Diagnostic Test
Lead sponsor: Rebiscan, Inc.; Industry
Eligibility: 13 Years to 45 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acromegaly
Interventions: Pasireotide (SOM230), Octreotide (Sandostatin); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 5
States / cities: Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more

Conditions: Cancer
Interventions: docetaxel, thalidomide; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Post Dural Puncture Headache
Interventions: Caffeine, saline; Drug
Lead sponsor: United States Naval Medical Center, Portsmouth; Federal
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Portsmouth, Virginia

Conditions: Childhood Absence Epilepsy
Interventions: Cannabidiol Oral Solution; Drug
Lead sponsor: Radius Pharmaceuticals, Inc.; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 11
States / cities: Miami, Florida • Tampa, Florida • Atlanta, Georgia + 8 more

Search by objective public record fields.

Temporal Interference Brain Stimulation for Adults With Drug-Resistant Epilepsy Undergoing Stereo-EEG Monitoring

Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients

Brain Injury Biomarkers in the General Population

Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

Developmental Phenomenology of Obsessive Compulsive Disorder and Tourette Syndrome in Children and Adolescents

A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy

Risk Stratification in Children With Concussion

Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device

Reproductive Health in Men and Women With Vasculitis

A Dyadic Sleep Intervention for Alzheimer's Disease Patients and Their Caregivers

Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor

Improving Recovery After Stroke Via Electrical Stimulation of Proprioceptors

Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma

000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Psychosocial/Behavioral Intervention in Post-Stroke Depression

Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency

Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease.

HITT for the Identification of Mild Traumatic Brain Injury

Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

Caffeine Versus Placebo for Spinal Headaches

Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures